Treatment with corticosteroids was initiated, followed by the introduction of weekly subcutaneous tocilizumab, an IL-6 inhibitor, ultimately resolving both his APS and its underlying cause, giant cell arteritis. Here, IL6 is linked to temporal arteritis.